Yahoo · Sep 3, 2026
Sector Update: Healthcare Stocks Edge Higher Late Afternoon
Healthcare stocks were slightly higher late Thursday afternoon, with the NYSE Healthcare Index incre
AP
NASDAQ · APGE
Apogee Therapeutics, Inc.
Healthcare · Biotechnology
$135.07
Up+$0.00 (+0.00%)
Updated Sep 16, 2026, 11:12 AM
SID Score
6.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.84B
- P/E ratio
- -16.22
- Dividend yield
- 0.00%
- 52-week range
- $35.39 – $135.09
- Volume
- 5.14M
- Avg. volume
- 981.84K
Price performance
APGE price history
1M range · 12 trading sessions · Daily adjusted prices
APGE closed at $135.07 after 12 trading sessions, up 0.37% for the selected period.
- Last close
- $135.07
- Period change
- +0.37%
- Period low
- $134.57
- Period high
- $135.08
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $135.08 | $135.09 | $135.06 | $135.07 | 5.14M |
| Sep 1, 2026 | $135.03 | $135.09 | $135.01 | $135.08 | 1.09M |
| Aug 31, 2026 | $135.00 | $135.08 | $134.99 | $135.08 | 1.81M |
| Aug 28, 2026 | $134.95 | $134.975 | $134.93 | $134.97 | 733.86K |
| Aug 27, 2026 | $134.93 | $134.98 | $134.91 | $134.96 | 1.14M |
| Aug 26, 2026 | $134.83 | $134.99 | $134.81 | $134.95 | 1.61M |
| Aug 25, 2026 | $134.85 | $134.86 | $134.81 | $134.85 | 655.84K |
| Aug 24, 2026 | $134.75 | $134.83 | $134.71 | $134.79 | 1.15M |
| Aug 21, 2026 | $134.79 | $134.82 | $134.70 | $134.75 | 948.28K |
| Aug 20, 2026 | $134.72 | $134.80 | $134.68 | $134.75 | 1.16M |
| Aug 19, 2026 | $134.83 | $134.88 | $134.70 | $134.71 | 1.42M |
| Aug 18, 2026 | $134.55 | $134.60 | $134.54 | $134.57 | 992.19K |
Latest APGE news
The latest Smart Investors Daily articles mentioning APGE.
Stock researchCompany · Overview
APGE research
Overview
Company profile and research snapshot.
Company profile
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $90.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Truist Securities | Hold | — |
| Aug 12, 2026 | BTIG | Neutral | — |
| Jun 24, 2026 | Stifel | Hold | — |
| Jun 24, 2026 | TD Cowen | Hold | — |
| Jun 24, 2026 | Mizuho | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 3, 2026
ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.
Yahoo · Sep 3, 2026
AbbVie Completes Acquisition of Apogee Therapeutics
AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.
Yahoo · Sep 2, 2026
Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says
Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
